Stay updated on TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The site footer now displays revision v3.8.1 instead of v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-18T01:35:53.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The record provides details of the TTI-622 and daratumumab hyaluronidase-fihj study for relapsed or refractory multiple myeloma, including its design, participant criteria, and outcome measures. The study is listed as completed and is no longer recruiting.
    Difference
    51%
    Check dated 2026-11-10T21:50:14.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden message instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T22:51:26.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A sitewide NIH notice about using “Super Intelligence” instead of “Artificial Intelligence” appears above the 403 error page. The site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T21:59:52.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-06T22:07:05.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, indicating restricted access to the content. The page shows a minimal error layout with a 403 message and a Home link, preventing access to the trial details.
    Difference
    0.5%
    Check dated 2026-09-29T22:10:29.000Z thumbnail image

Stay in the know with updates to TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.